Healthcare Industry News: antibiotic
News Release - March 27, 2013
AdvanDx, Inc. Elects Former Roche Molecular Systems CEO, Heiner Dreismann, Ph.D., to its Board of DirectorsBOSTON--(Healthcare Sales & Marketing Network)--AdvanDx, Inc. announced today that Heiner Dreismann, Ph.D., has joined its board of directors as an independent director.
“We are extremely pleased to welcome Heiner as the newest member of the AdvanDx board of directors,” said Dennis H. Langer, M.D., J.D., Chairman and Chief Executive Officer of AdvanDx. “Heiner brings an valuable industry perspective as a director – he has both the breadth of experience throughout the diagnostics industry that will help us expand our core business, as well as a deep understanding of how to develop and commercialize novel molecular diagnostics products for infectious diseases, where our business is focused today. This expertise will provide us with unique insights that will assist us in executing on our mission to develop market-leading, next-generation molecular diagnostic products that make a difference for our customers and their patients, both in the United States and internationally.”
Dr. Dreismann has had a distinguished career in the diagnostics industry, both as a senior operating executive and as a director of both public and private companies. Dr. Dreismann was an executive at the Roche group from 1985 to 2006, where he held several senior positions, including President and CEO of Roche Molecular Systems and a member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves as a director on the board of directors of several public and private health care and diagnostic companies, including Myriad Genetics, Inc. Dr. Dreismann earned an M.S. in Biology and Ph.D. in Microbiology/Molecular Biology summa cum laude from Westfaelische University (The University of Munster) in Germany.
About AdvanDx, Inc.
AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. Our mission is to improve antibiotic decision-making and patient outcomes while limiting unnecessary and inappropriate antibiotic use and reducing healthcare costs.
AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH®) technology platform. This technology enables fast and highly accurate single cell analysis for bacterial species identification in samples from patients with critical infections.
AdvanDx is the market leader in molecular testing of positive blood cultures enabling clinical microbiology labs to report pathogen identification results 48 to 72 hours earlier than with conventional testing methods. When used by physicians and pharmacists to ensure early, appropriate antibiotic therapy for patients with bloodstream infections, including septicemia, AdvanDx’s PNA FISH® tests have been shown in clinical studies to reduce mortality rates, shorten the length of hospital stay, and lower hospital costs.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.